GSK's mRNA Flu Vaccine Advances to Late-Stage Clinical Development After Positive Trial Results

By Christian Moess Laursen

GSK said its would move its seasonal mRNA flu vaccine to late-stage clinical development after positive Phase 2 trial results.

The British pharma giant said Thursday that the trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza type A and B.

There are four types of influenza viruses, with A and B being the two types that cause most human illness and that are responsible for flu seasons each year.

In both younger and older adults, pre-defined success criteria were met in the Phase 2 trial, GSK said.

The mRNA seasonal influenza vaccine program would now progress into late-stage clinical development, or Phase 3, GSK said.

"Ultimately, our goal is to develop a new best-in-class vaccine to bring greater protection to people through the influenza season," chief scientific officer, Tony Wood, said.

In July, GSK signed a new licensing agreement with CureVac to assume full control of developing and manufacturing influenza and Covid-19 candidate vaccines.

Write to Christian Moess Laursen at christian.moess@wsj.com

(END) Dow Jones Newswires

September 12, 2024 02:50 ET (06:50 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.